While important in carcinogenesis, the role of Ras in normal self-renewing tissues such as epidermis is unclear. To address this, we altered Ras function in undierentiated and dierentiating epidermal layers. Ras blockade within undierentiated basal epidermal cells leads to decreased integrin expression, diminished growth capacity and induction of dierentiation. Ras blockade in post-mitotic suprabasal epidermis exerts no eect. In contrast, regulated Ras and Raf activation inhibits dierentiation. These ®ndings indicate that spatially restricted Ras/Raf signaling divides epidermis into an undierentiated proliferative compartment and a dierentiating post-mitotic compartment and suggest a new role for Ras in tissue homeostasis.
Introduction
Normal epidermis is a self-renewing tissue that maintains homeostasis via precise control of cellular proliferation. This strati®ed epithelial tissue contains a basal layer of mitotically active cells which cease proliferating, migrate outwards and activate expression of terminal dierentiation genes. Previously identi®ed positive growth in¯uences, including those acting via receptor tyrosine kinases and integrins, may function in part through Ras GTPases (Shields et al., 2000) .
Depending on the cell type and experimental conditions, Ras can either promote or inhibit dierentiation via evolutionarily conserved eectors that include the Raf/MEK/MAP kinase cascade (Ewen, 2000; Shields et al., 2000) . In muscle cells, it appears that Ras predominantly inhibits dierentiation (Konieczny et al., 1989; Olson et al., 1987) . In contrast, evidence that Ras promotes growth arrest and cellular dierentiation has been obtained in cultured neuronal, adipocyte and myeloid cell lines (Crespo and Leon, 2000; Kozma et al., 1993; Qui and Green, 1992) . In the case of myeloid cell lines, however, strong Ras signal has shown divergent results with respect to dierentiation, possibly as a result of dierences in cell culture conditions (Crespo and Leon, 2000) . Contradictory data have also arisen regarding Ras eects in adipocytes indicating that Ras can induce adipocyte proliferation under some conditions instead of dierentiation (Ruiz-Hidalgo et al., 1999) . Therefore depending on the experimental setting in vitro, Ras can induce opposite eects, frustrating con®dent assignment of a physiologic role for Ras in a given tissue and underscoring the need for in vivo studies.
In skin, a role for Ras in epidermal carcinogenesis has been suggested. Activating mutations in Ras occur in neoplasms such as human squamous cell carcinoma (SCC) (Pierceall et al., 1991) and in experimental SCC induction in mice (Yuspa, 1994) . Transgenic mice expressing active Ras mutants via promoter constructs that target suprabasal epidermal cells produce papillomas at sites of wounding over time that do not progress to carcinomas (Bailleul et al., 1990; Greenhalgh et al., 1993b) . Basal layer promoter-driven active Ras expression from the K5 promoter, however, leads to growths that progress to undierentiated neoplasias (Brown et al., 1998) . These data point to Ras as a factor in epidermal cancer, however, they do not address a potential role for Ras in the physiologic control of growth and dierentiation in epidermis.
In epidermal cells, con¯icting data exists on the eect of Ras and its Raf/MEK/MAPK eectors on growth and dierentiation. Several in vitro studies have reported that the pathway supports cellular proliferation and resists dierentiation (Mainiero et al., 1997; Zhu et al., 1999) . In contrast, other work demonstrated that constitutive Ras/Raf activation induces growth arrest and features of terminal dierentiation in cultured murine keratinocytes (Lin and Lowe, 2001; Roper et al., 2001) . In the latter case, two studies dier in reporting that growth arrest is either p19 ARF -dependent (Lin and Lowe, 2001) or independent (Roper et al., 2001) . In contrast to this, prior studies in murine keratinocytes had demonstrated that viral expression of Ras inhibits dierentiation and stimulates growth (Dlugosz et al., 1994) . Thus, work to date in Figure 1 Altering epidermal Ras activity. (a) Active Ras assay. Primary human keratinocytes were transduced with retroviral expression vectors for dominant-negative RasN17, constitutively active RasV12 and lacZ control. 24 h later, active Ras was recovered by GST-Raf Binding Domain (RBD) anity precipitation and detected by anti pan-Ras antibody. Note inhibition of GTP-bound Ras by RasN17 below the level of unstimulated control and induction by RasV12 (top, panel), although both show similar Ras overexpression (total Ras, second panel). lacZ transduced cells treated with EGF con®rm the ability to detect induction of GTP-bound active Ras in these cells. (b) Altering epidermal Ras activity in transgenic mice. Mice transgenic for keratin 14 (K14) or keratin 1 (HK1)-targeted expression of dominant-negative RasN17 (N17) and active RasV12 (V12) were generated. Spatially localized expression of Ras proteins was con®rmed immunochemically. Note expression of Ras protein predominantly in the basal layer of normal tissue, its suprabasal location in HK1-N17 tissue and enhanced basal layer expression in K14-N17 tissue. NL=normal littermate control; control=background obtained with no primary antibody; dotted line denotes the epidermal basement membrane zone (BMZ). Scale bars=30 mm. (c) Histology of K14-RasN17 and K14-RasV12 transgenic mice at birth. Note epidermal thinning and hyperkeratosis in K14-RasN17 skin in contrast to massive hyperplasia with absence of normally dierentiated granular and corni®ed layers in K14-RasV12 tissue. Note the entirely normal appearance of HK1-N17 tissue. Scale bars=60 mm. (d) Proliferation marker expression in K14-RasN17 and wild-type littermate control (NL). In normal newborn cultured epidermal cells provides opposing and often directly contradictory ®ndings regarding Ras impacts on epidermal growth and dierentiation.
Published work to date is subject to several major challenges that may account for these disparities. First, most studies rely on inducing strong constitutive activation of the Ras/Raf/MEK/MAPK cascade components in a manner unlikely to occur in physiologic signaling. It is well known that this can produce discrepancies because Ras eects can dier dramatically depending on both signal strength and duration (Marshall, 1999) . Second, these experiments were constrained to cultured cells which lack factors found in vivo that are necessary for normal signal integration such as matrix cues. Finally, similar to transgenic mice studies of Ras in epidermal neoplasia, these experiments focused only on strong gain-of-function unbalanced by loss-of-function studies. If Ras and its eectors play a physiologic role in epidermis, then approaches to block Ras may avoid potentially confounding eects of ectopic overexpression of constitutively active mutants.
Here we have used two general approaches to identify a spatially localized functional role for Ras in epidermis. First, we have blocked Ras function in vivo in both undierentiated and dierentiating epidermis using targeted expression of a dominantnegative Ras mutant. Second, we have both activated and blocked Ras/Raf activity at a range of signal strengths in primary epidermal cells. Our ®ndings indicate that Ras/Raf signaling acts in a dosedependent manner within undierentiated cells to support proliferation while actively opposing entry into the post-mitotic dierentiation pathway. These data support a model in which spatially restricted Ras activity divides epithelium into two distinct cellular compartments and suggest a major role for Ras in epidermal homeostasis.
Results

Altering epidermal Ras activity in transgenic mice
To study the eects of altering epidermal Ras function in vivo, we endeavored to inhibit Ras activity in this tissue compartment. Ras proteins demonstrate functional redundancy from yeast to mammals (Shields et al., 2000) . Because of such redundancy, we used a dominant interference approach. First, we con®rmed the ability of the dominant-negative Ras inhibitory mutant, RasN17, to inhibit Ras activation in epidermal cells. To do this, we directly measured the levels of active GTP-bound Ras in cells expressing either RasN17 or the constitutively GTP-bound active RasV12 mutant positive control. Both Ras mutants were expressed at similar levels ( Figure 1a , lanes 3 and 4, middle panel) in primary human keratinocytes but exerted the expected opposite eects on Ras activation. RasN17 decreases levels of endogenous active Ras, con®rming its ability to block Ras in epidermal cells ( Figure 1a , lanes 1 and 3, top panel). In lacZ transduced controls, addition of epidermal growth factor (EGF) elevated GTP-bound Ras levels but to lower levels than those seen with RasV12 expression 24 h post-transduction ( Figure 1a , lanes 2 and 4, top panel). Dominant-negative Ras was then targeted to the epidermis of transgenic mice. Two dierent promoters were used, the basal layer keratin 14 (K14) promoter that targets undierentiated cells (Vassar et al., 1989) and the suprabasal layer keratin 1 (HK1) promoter targeting dierentiating cells (Greenhalgh et al., 1993a) . Genetically matched active K14-RasV12 transgenic mice controls were also generated ( Table 1) . As con®rmed by immunostaining with anti-Ras antibodies recognizing both wild-type and mutant proteins, these promoters target Ras proteins to either undierentiated basal layer cells or to those in the dierentiating suprabasal layers as expected (Figure 1b) . Severely aected K14-RasN17 mice displayed thin, shiny skin and limb defects (data not shown), dying within 1 ± 3 days after birth while all HK1-RasN17 mice were entirely normal, suggesting that the primary site of epidermal Ras function resides within the basal layer. The dierences in K14-RasN17 phenotypes within the same line correlated with gene copy number. In contrast to the massive epidermal hyperplasia with absence of dierentiating layers that is seen in K14-RasV12 mice, which die at birth, newborn RasN17 epidermis was thin with an increase in thickness of the terminally dierentiated stratum corneum ( Figure  1c ) and decreased numbers of actively cycling cells ( Figure 1d ). K14-RasN17 mice displayed normal transepidermal water loss (data not shown), con®rm-ing that barrier perturbation does not account for these ®ndings.
Mildly aected K14-RasN17 mice expressing lower levels of epidermal RasN17 survived to adulthood, however, these mice spontaneously developed widespread super®cial skin erosions by 6 weeks of age (data not shown). These erosions were not due to trauma or blistering and were characterized by non-healing loss of viable epidermis associated with infection and death. These ®ndings were not associated with changes in the number of TUNEL(+) cells compared to control (Figure 1e ), indicating that Ras blockade may aect proliferative epidermal self-renewal without aecting cell death.
Ras blockade leads to decreased epithelial cell proliferative capacity
The widespread epidermal erosions that develop in surviving transgenic mice with epidermal Ras blockade raise the possibility that Ras may help sustain proliferative capacity of epidermal progenitor cells. To test this, we used high eciency (499%) retroviral gene transfer without drug selection to primary human keratinocytes Robbins et al., 2001) . Ras function was altered by expressing wild-type or dominant-negative Ras and then the proliferative capacity of resulting clones was examined. High levels of active RasV12 have been observed to cause growth arrest of primary cells (Hahn et al., 1999; Serrano et al., 1997) , including primary keratinocytes (Lin and Lowe, 2001 ). Therefore we used wild type H-Ras to control for induced protein expression and other potential non-speci®c eects as it does not produce strong levels of Ras signal unless activated by additional stimuli (data not shown). In keratinocytes seeded at low density (Zhu et al., 1999) , Ras blockade Figure 3 Ras promotes epidermal integrin expression. b1 and b4 integrin expression was detected by immunostaining K14-RasN17 (N17), K14-RasV12 (V12) and normal littermate (NL) skin. Note decreased b1 and b4 integrin expression in K14-RasN17 skin and increased expression in K14-RasV12 skin extending up into suprabasal cells. Scale bars=30 mm 
Ras promotes epidermal integrin expression
Both b4 and b1 integrin have been implicated as important in epidermal cell proliferative capacity and stem cell function (Li et al., 1998; Watt, 1998) . To determine if Ras promotes expression of such progenitor markers, we studied expression of b4 and b1 integrin as a function of Ras activity. While Ras blockade is associated with decreased expression of b4 and b1 integrin, active Ras increases expression both in transgenic epidermis ( Figure 3 ) and in primary cells in culture transduced at high eciency with RasV12 retrovectors (data not shown). In the latter case, integrin upregulation occurs even during cell-cycle arrest induced by strong constitutive Ras signaling, indicating that integrin induction by Ras is not merely a byproduct of enhanced cellular proliferation.
Ras suppresses epidermal differentiation
The histologic and cell proliferative ®ndings above indicate that Ras inhibits dierentiation in nontransformed epidermal cells and that Ras blockade allows unopposed dierentiation to proceed along with a loss of proliferative capacity. Consistent with this hypothesis, Ras blockade leads to epidermis with high levels of dierentiation markers such as K10, K1, loricrin, ®laggrin and involucrin while epidermal Ras activation inhibits expression of these markers ( Figure  4a and data not shown). To further examine this process, we studied Ras pathway impacts on dierentiation in primary human keratinocytes in vitro. Normal cells were transduced with either RasV12, RasN17 or lacZ control. While active RasV12 inhibits both basal and calcium-induced levels of dierentiation markers K1, K10 and involucrin, dominant-negative RasN17 dramatically increases their expression ( Figure  4b and data not shown). In both cases, altering Ras function overrides the extracellular calcium dierentiation signal, suggesting a potentially dominant role for Ras in cellular integration of dierentiation stimuli and the need for a continual Ras signal to prevent cells from entering the terminal dierentiation pathway.
Control of differentiation via regulated activation and blockade of Ras
While demonstrated to inhibit dierentiation in murine keratinocytes in earlier studies (Roop et al., 1986; Yuspa et al., 1983) , Ras has also been observed to induce dierentiation (Lin and Lowe, 2001; Roper et al., 2001) . These latter studies where Ras promotes dierentiation, however, may be confounded by the fact that cells underwent drug selection prior to analysis. This is important because Ras/Raf eects can vary with dose and drug selection can promote keratinocyte dierentiation (Stockschlader et al., 1994) . To avoid this pitfall, we expressed regulated active and dominant Ras mutants in primary human epidermal cells via a high eciency gene transfer approach without drug selection .
Regulated Ras mutants were generated via Nterminal fusion of the estrogen receptor (ER) ligand binding domain, an approach used successfully to generate C-terminal Raf1 fusions conditionally responsive to 4-hydroxytamoxifen (4OHT) (Woods et al., 1997) . Addition of 4OHT at a range of doses to cells expressing ER:RasV12 and ER:RasN17 was used to either activate or block Ras signal transduction, respectively. Regulated Ras function was con®rmed by levels of phosphorylated downstream MAP kinases ERK1 and ERK2. Ras inhibition led to dierentiation in a dose-dependent manner (Figure 4c ). Induction of active Ras, on the other hand, inhibited dierentiation marker expression, also in a dose-dependent manner (Figure 4d ). In agreement with in vivo ®ndings above, these regulated data suggest that Ras acts as a potent regulator of epidermal dierentiation and that it inhibits entry into the dierentiation program.
Downstream Ras effector pathways
Ras action can proceed via direct binding to initiators of its three major downstream eector cascades, Raf, RalGDS and PI3K (Gille and Downward, 1999; Shields et al., 2000) . Which of these eector pathways contribute to Ras eects in epidermal cells? To begin to address this question, we utilized Ras mutants which predominantly induce either Raf, RalGDS or PI3K (White et al., 1995) . When expressed in primary keratinocytes, the Rafactivating mutant was most potent at inhibiting dierentiation gene expression (Figure 5a ), suggesting that signaling through Raf may be important in Ras inhibition of dierentiation. Because Ras does not activate the PI3K eector pathway in all cell types, we con®rmed that Ras activity in primary epidermal cells leads to activation of the PI3K downstream eector, Akt, as measured by phosphorylation (Figure 5b ). To further examine the role of Raf and PI3K eectors, we incubated primary cells with inhibitors of either the Ras/Raf downstream target MEK or PI3K. MEK inhibition with two distinct inhibitors strongly induced dierentiation gene ex- (Figure 5d ). While displaying comparable amounts of total MAPK, K14-RasN17 transgenic mouse epidermis shows minimal active MAPK, con®rming inhibition of the Ras/Raf/MAPK cascade by RasN17 (Figure 5d and data not shown). In contrast, K14-RasV12 epidermis shows signi®cant increases in active MAPK expression, both in the basal layer as well as in suprabasal layers where the K14 promoter is expressed within hyperproliferative epidermis (Figure 5d ). In HK1-RasN17 epidermis, active MAPK expression is not observed in suprabasal layers as expected (data not shown). These data suggest that spatially restricted Raf/MEK/MAPK action within the basal layer of epidermis contributes to Ras epidermal eects and con®rm transgenic epidermis with features of either blocked or enhanced function of this eector pathway.
Raf inducibly stimulates epithelial cell proliferation and inhibits differentiation
In contrast to our in vivo data indicating Ras promotes epidermal growth, we observed irreversible growth arrest after overexpression of constitutively active Ras and Raf1 in normal keratinocytes via retroviral transduction in vitro (data not shown), similar to that reported in other epithelial and non-epithelial cell types (Hahn et al., 1999; Serrano et al., 1997) . These data suggest that cells possess a protective cell growth arrest mechanism against oncogenic Ras/Raf activation. The eects of Ras and its eectors, however, are known to vary depending on signal magnitude and duration (Halfar et al., 2001; Marshall, 1999; Roovers and Assoian, 2000) . Retroviral gene transfer produces up to 100-fold more expression of delivered genes in our hands than does expression via keratin promoters in transgenic epidermis. This may account for the disparity observed between Ras growth eects in the two settings and suggested a dosage eect.
To see if signal strength could account for this disparity, we modulated signal magnitude through the Ras downstream eector Raf. To do this, we generated a retrovirus expressing a regulated Raf-1 fused to a mutant ligand binding domain of the murine estrogen receptor that can be regulated by exogenous tamoxifen (4OHT) (Woods et al., 1997) . While 4OHT at low and high dose exerted no growth eects on control keratinocytes, in Raf:ER expressing keratinocytes low doses produced proliferation. In contrast, higher 4OHT doses inhibited cell growth (Figure 6a ), indicating that Ras/Raf eects on growth of epidermal cells are dosedependent. Raf also exerted signal strength-dependent suppression of calcium induced dierentiation markers (Figure 6b,c) , similar to inducible Ras.
The RasN17 mutant, while selective for Ras blockade, has also recently been shown capable of acting independently of Ras in some cell types by inhibiting the downstream transcription factor Elk-1 in NIH3T3 cells (Stewart and Guan, 2000) . If RasN17 triggers dierentiation through Ras blockade, then its eects should be reversed by activating pathway components downstream of Ras such as Raf. Inducible Raf thus oers the opportunity to determine whether RasN17 eects on epidermal dierentiation occur via Ras inhibition or through unrelated actions on downstream eectors such as Elk-1. To test this, we coexpressed RasN17 with Raf:ER in primary human keratinocytes. Raf induction by 4OHT in this setting completely suppresses dierentiation marker expression enhanced by RasN17 (Figure 6d ). This con®rms that RasN17 dierentiation eects can be circumvented by activating downstream eectors of the Ras/Raf cascade. Furthermore, we con®rmed that RasN17 exerts no eect on Elk-1 expression or Elk-1-driven reporter gene activity in keratinocytes (M Yamazaki et al., unpublished) . These data suggest that the dierentiation eects of the RasN17 mutant occur via blockade of the Ras/Raf pathway rather than through unrelated downstream mechanisms.
Discussion
Our ®ndings suggest a model in which homeostatic control of epidermal growth and dierentiation involves spatially localized Ras action that divides the epidermis into undierentiated and dierentiating cellular compartments (Figure 7) . This model posits that Ras acts primarily within the basal layer cell compartment where proliferating cells reside. It predicts that its blockade there would lead to the ®ndings of hypoplasia, induction of dierentiation and proliferative exhaustion while its blockade in dierentiating cells would exert no eect, consistent with our ®ndings. In this setting, Ras signaling is necessary to maintain cells in the proliferative, undierentiated state and a loss of Ras function leads to a decrease in proliferative capacity and subsequent entry into the terminal dierentiation pathway. This model is based on our observation that basal layer Ras blockade leads to a thin, highly dierentiated epidermis that appears to undergo spontaneous loss of proliferative selfrenewal, resulting in widespread skin erosions. This model is also based on the observation that Ras activation produces the opposite picture, a highly proliferative undierentiated epidermis expressing key integrins characteristic of the epidermal progenitor cell compartment.
Ras blockade in stratified epithelium
We have attempted to block Ras pathway action in epidermis using a well characterized dominant interference approach. We have done this because of Ras redundancy in mammals, as evidenced by a lack of overt skin phenotypes in H-Ras 7/7 (Ise et al., 2000) , N-Ras animals (Johnson et al., 1997) . The fact that all Ras isoforms must be deleted in yeast in order to see a phenotype suggests that truly null Ras tissue in mammals may only be obtained by removing at least H, N and K-Ras simultaneously, and possibly additional Ras-related genes as well (Shields et al., 2000) . Consistent with Ras redundancy, there is a compensatory increase in other Ras proteins in HRas 7/7 skin (Ise et al., 2000) . The eectiveness and speci®city of blockade by RasN17 has been con®rmed in a number of ways. First, RasN17 decreases levels of endogenous GTP-bound Ras in epidermal cells. Second, this dominant-negative mutant also decreases levels of active MAPKs both in vitro and in vivo, indicating it inhibits the Ras/Raf/MEK/MAPK cascade. Third, pharmacologic blockade of the cascade using inhibitors to MEK recapitulates the eects of RasN17. Fourth, RasN17 eects on dierentiation can be reversed by inducible Raf, suggesting that RasN17 does not directly activate dierentiation in a Rasindependent manner. Finally, in epidermal cells RasN17 fails to alter the expression and transcriptional activity of Elk-1, a Ras-independent eect which has been observed in NIH3T3 cells. These ®ndings indicate that RasN17 faithfully blocks the Ras/Raf/MEK/ MAPK cascade in epidermal cells.
Spatial localization of Ras action
Although all Ras proteins are expressed in skin tissue extracts (Ise et al., 2000) , the importance of the localization of Ras function within epidermis has not been characterized. Our data provides several lines of evidence to suggest that Ras regulation of growth and dierentiation is spatially con®ned to basal epithelial cells attached to the basement membrane. First, we observe Ras protein is localized to basal layer cells within normal epidermis. Second, the use of promoters targeting dierentiated versus undierentiated cells demonstrated dramatically dierent impacts of altering Ras function depending on which layer of epidermis was targeted. Activating or blocking Ras function in basal layer cells produces dramatically opposing eects. On the other hand, altering Ras function in the suprabasal post-mitotic compartment via either activation (Bailleul et al., 1990; Greenhalgh et al., 1993b) or blockade as we have shown here, fails to directly impact the tissue, although in the case of the former, papillomas appear over time at sites of trauma. Finally, in addition to our promoter-targeted ®ndings with transgenic mice, we have observed that phosphorylated MAPK is localized primarily within cells of the basal layer of normal epidermis. Such basal layer active MAPK is abolished in K14-RasN17 tissue, suggesting that a major site of Ras signaling may reside in this location and that Ras provides important regulatory stimuli for MAPK in epidermis.
Regulation of cellular proliferative capacity
Apparently contradictory data exists regarding the ability of the Ras/Raf/MAPK cascade to either inhibit growth of epidermal cells (Lin and Lowe, 2001; Roper et al., 2001) or to promote it (Roop et al., 1986; Zhu et al., 1999) . We report both eects here. We have demonstrated that growth eects in epidermal cells are dependent on signal strength. Retroviral RasV12 expression is sucient to cause growth arrest in epidermal cells. Short-term RasV12 expression leads to signi®cantly elevated levels of active GTP-bound Ras. Such strong constitutive Ras/Raf signaling is known to trigger senescence via proteins such as ARF, p16
INK4A and p53 in a wide variety of other cell types in what has been postulated to serve as a protection against inappropriate signaling by oncogenic Ras (Elenbaas et al., 2001; Ferbeyre et al., 2000; Hahn et al., 1999; Malumbres et al., 2000; Serrano et al., 1997) . In this regard, we were unable to detect any dierences in the expression of ARF or p53 proteins during growth arrest induced by high levels of Ras/Raf signaling (data not shown), indicating that this process may involve other cell cycle regulatory genes in human epidermal cells. We believe that prior studies in epidermal cells reporting growth inhibition by Ras/ Raf are observing a protective response against high level signaling by oncogenic Ras/Raf and that this does not re¯ect the impact of physiologic activation in the tissue. Consistent with this possibility is the fact that these eorts used either retroviral overexpression of RasV12 (Lin and Lowe, 2001 ) or a strongly induced Raf:ER fusion with 200 nm 4OHT (Roper et al., 2001) , twice the maximal level at which we observed growth inhibition.
Our data indicate that Ras function is required for epidermal self-renewal because Ras blockade in vivo leads to epidermal hypoplasia, widespread skin erosions and death. In support of this, Ras inhibition depletes the proliferative capacity of primary epidermal cells and low signal strengths of Raf activation stimulate proliferation. These ®ndings are consistent with a recent study involving targeted disruption of the a-catenin gene which increases epidermal Ras and MAPK activity and epidermal proliferation in vivo (Vasioukhin et al., 2001) . Similar ®ndings were also recently reported in both human psoriasis and a transgenic mouse model with psoriatic features generated by suprabasal expression of integrin b1. In both cases induction of active MAPK was observed with hyperproliferation and inhibition of terminal dierentiation; expression of active MEK in keratinocytes cultured in vitro on dermal equivalents induced similar features (Haase et al., 2001) . A role for Ras/ Raf/MEK/MAPK in epidermal proliferation is further supported by the ®nding that Ras supports keratinocyte proliferation in culture in a manner involving a6b4 integrin and Shc (Mainiero et al., 1997) . In further agreement is work demonstrating that MAPK function supports both integrin expression and proliferation by epidermal progenitors (Zhu et al., 1999) . Consistent with a role for Ras eectors in inducing integrins that support proliferative capacity, another recent study demonstrated that Raf and MEK increase expression of other integrins, namely a6 and b3, in NIH3T3 and endothelial cells (Woods et al., 2001) . Acting synergistically with integrins, proproliferative growth factors such as EGF are the best characterized activators of Ras in epithelial cells (Mainiero et al., 1997) , further supporting a role for Ras in epidermal growth promotion, however, the precise relationship of Ras and integrin signaling in epithelia remain to be determined. Finally, analysis of Raf targets in breast epithelial cells via gene expression pro®ling demonstrated that Raf's primary eects on growth regulatory genes were to induce genes promoting cellular proliferation (Schulze et al., 2001) . Taken together, these data are consistent with a physiologic role for Ras in maintaining the proliferative capacity of epithelial progenitors in a process involving the Raf/MEK/MAPK eector cascade.
Regulation of differentiation
Ras/Raf signaling has been implicated in promoting dierentiation of epidermal cells in some studies (Lin and Lowe, 2001; Roper et al., 2001) and opposing it in others (Dlugosz et al., 1994; Zhu et al., 1999) . These prior eects have relied on in vitro analysis of Ras dierentiation eects, which can generate con¯icting results depending on the cell line and culture system used (Shields et al., 2000) . In this regard, studies reporting dierentiating eects of Ras/Raf occurred after the profound stress of cellular drug selection using agents such as G418 that promotes keratinocyte dierentiation (Stockschlader et al., 1994) .
Based on gain and loss of function experiments, both in vitro and in vivo, we believe that Ras signaling actively inhibits epidermal dierentiation in cells early in the dierentiation pathway. If this is true, then activation by a number of approaches should inhibit dierentiation and blockade by several means should induce it, consistent with our observations. In vivo, expression of active Ras inhibits epidermal dierentiation markers and leads to absence of normal dierentiated granular and corni®ed layers. In vitro, unselected primary epidermal cells in which Ras and Raf signaling is activated at a range of signal strengths demonstrate inhibition of dierentiation gene expression in a dose-dependent manner. Ras blockade in transgenic epidermis, on the other hand, induces high levels of dierentiation markers and prominent stratum corneum formation suggesting that Ras inhibition leads to enhanced dierentiation. Consistent with this, RasN17 expression in primary epidermal cells also induces dierentiation markers and this can be triggered via an inducible ER:RasN17 fusion as well. Finally, pharmacologic blockade of MEK leads to dierentiation gene induction. Taken together, these in vivo and in vitro data indicate that Ras signaling actively inhibits epidermal dierentiation.
What is the role of downstream Ras eectors in inhibiting epidermal dierentiation and are they merely a byproduct of those promoting proliferative capacity? Recent studies in transformed epithelial cells such as the aneuploid HaCaT cell line oer additional avenues whereby Ras eectors may oppose dierentiation, such as by inhibiting intracellular calcium level elevation (Shi and Issero, 2000) . Other studies with the HaCaT line indicate that MAPK is induced transiently during calcium-induced dierentiation in a Ras-independent fashion (Schmidt et al., 2000) . However, the majority of the latter data were generated using an aneuploid transformed cell line, a setting where Ras/Raf eects can dier signi®cantly from non-transformed cells (Shields et al., 2000) . Transient MAPK activation may be mechanistically distinct from that induced by Ras signaling via factors such as EGF. This is consistent with our ®ndings as EGF activated Ras and inhibited the dierentiation marker involucrin even in transformed HaCaT cells (Schmidt et al., 2000) . Furthermore, divergent Ras eectors could exert diering eects on dierentiation. In support of this, the epidermal dierentiation marker cystatin A has recently been shown repressed by Ras/Raf/MEK/ MAPK in human keratinocytes, consistent with our ®ndings here, but induced by the alternate MEKK1/ MKK7/JNK pathway (Takahashi et al., 2001) . Our data supports such divergent eects by demonstrating that PI3K blockade inhibits dierentiation marker expression. The de®nitive understanding of the speci®c roles of individual Ras eectors and how their speci®c eects are integrated in cellular decision-making regarding dierentiation awaits further study.
In summary, our ®ndings suggest that the Ras/Raf signaling cascade acts in a spatially restricted and signal strength-dependent fashion to promote epidermal proliferative capacity and to actively oppose the onset of dierentiation. These data have implications for future eorts to understand the regulation of epithelial growth and dierentiation and in developing new therapeutics for disorders of these processes.
Materials and methods
Cell growth and gene transfer
Amphotropic retrovectors were produced and human keratinocyte cell culture and gene transfer performed as described (Choate et al., 1996b; Deng et al., 1998; Kinsella and Nolan, 1996) . Sequences for RasN17 (Feig and Cooper, 1988) and RasV12 (Serrano et al., 1997) were subcloned into the EcoRI site of LZRS (Kinsella and Nolan, 1996) . The regulated Raf1 Raf:ER vector was generated by subcloning the XhoI-EcoRI fragment of constitutively active RafDD (Woods et al., 1997) and the EcoRI-NotI fragment of 4OHT responsive mutant estrogen receptor a, ER TM (Pelengaris et al., 1999) into XhoI-NotI sites of LZRS. The ER-Ras construct was made by subcloning the BamHI-EcoRI fragment of ER TM in frame upstream of RasV12 and RasN17 in the LZRS. High eciency gene transfer was veri®ed by immuno¯uorescence and Western blotting as previously described using antibodies to Ras and ERa (Santa Cruz). MEK inhibitors were incubated with pre-con¯uent primary human keratinocytes for 24 h; PD098059 (20 mm; Calbiochem), U0126 (10 mm; Promega). For EGF studies, EGF was added at 50 ng/ml for 5 min.
Generation of transgenic animals
Sequences encoding RasN17 (Feig and Cooper, 1988) and RasV12 (Serrano et al., 1997) were subcloned downstream of a 2075-bp human keratin 14 (K14) promoter construct, which targets expression to keratinocytes within the basal epidermal layer (Vassar et al., 1989) , and used to produce transgenic mice. Sequence encoding RasN17 and was also subcloned downstream of human keratin 1 (HK1) promoter, a construct that targets gene expression to keratinocytes in the suprabasal epidermal layers (Greenhalgh et al., 1993a) , and used to generate additional transgenic mice. Transgene integration and copy number was con®rmed by PCR followed by Southern blot analysis.
Protein expression
The following antibodies were used in immunoblotting and in immunostaining (Seitz et al., 1998) ; rabbit anti-Ras (Santa Cruz, 1 : 200), rabbit anti-MAPKs p44 ERK1 and p42 ERK2 (New England Biolabs, 1 : 50), rabbit anti-phosphoserine 473 Akt (Cell Signaling, 1 : 1000), rabbit anti-phosphorylatedMAPKs p44 ERK1 and p42 ERK2 (Promega, 1 : 1000), rat anti-a-6 integrin (Chemicon, 1 : 200), mouse anti-®laggrin (Dale et al., 1987) (Biomedical Technologies Inc, 1 : 50), mouse anti-K10 (Ivanyi et al., 1989 ) (DAKO, 1 : 50), anti-K1 (Babco, 1 : 2500), anti-loricrin (Babco, 1 : 200), FITC-conjugated goat-anti-mouse IgG (Sigma, 1 : 150), FITC-conjugated goat-anti-rabbit IgG (Sigma, 1 : 150), TRITCconjugated rabbit-anti-rat IgG (Sigma, 1 : 200) . For immunoblotting (Choate et al., 1996a) , blots were stripped and reprobed with antibodies to b-actin (Santa Cruz, 1 : 4000) as an additional control for loading and extract quality. The active Ras pull-down assay was performed as described (de Rooij and Bos, 1997) .
Flow cytometry
Forty-eight hours post transduction cells were resuspended in FACS buer (PBS buer containing 2% BSA, 0.1% sodium azide, 1 mM CaCl 2 and 1 mM MgC 2 ). Cells were incubated on ice with b1 and b4 integrins using polyclonal b1 (Santa Cruz 1 : 50) and b4 (Chemicon 1 : 500) antibodies for 30 min. Data was acquired using the FACSTAR program.
Skin barrier function analysis
Transgenic and control skin were analysed for transepidermal water loss levels using an evaporimeter (Servomed) (Choate et al., 1996b) in the peri-natal period.
